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Arachidonate metabolites are potent mediators generated in endotoxin shock. Following endotoxin admin- 
istration (14 mg/kg) into unanesthetized rats, we found a rapid biliary secretion of peptide leukotrienes. 
Analysis of bile for peptide leukotrienes included organic solvent extractions, reversed phase-HPLC, radio- 
immunoassay (RIA), and spectrophotometry. The major imm~oreactive endogenous leukotriene (LT) 
from bile was eluted between LTC, and LTD, in three chromato~aphic systems. It corresponded thereby 
to a biliary metabolite of injected LTC, and LTD, which in turn showed the ultraviolet spectrum of a 
peptide leukotriene. This demonstration of endotoxin-induced generation of peptide LTs in vivo was possi- 
ble by sequential HPLC and RIA analyses in bile into which peptide LTs are eliminated from blood. 
~ak~triene Endotoxin Bile Radio~munoassay HPLC Eicosan~id 
1. INTRODUCTION 
Peptide leukotrienes LTG, LTD4, LTE4 and 
LTF4 as well as the dihydroxylated LTB4 are pro- 
ducts of arachidonate metabolism formed via the 
5lipoxygenase pathway [ 11. These compounds are 
mediators in anaphylactic and inflammatory reac- 
tions [1,2]. LTs have been demonstrated to elicit, 
on the other hand, many of the pathophysiologic 
symptoms 13-61 also observed in endotoxin shock, 
such as cardiac depression [7-91, augmentation of 
vascular permeability leading to tissue edema 
[lO,ll], and increased leukocyte adhesion to en- 
dothelial surfaces [12]. Endotoxins (LPS) are 
known to trigger the formation of cyclooxygenase 
[ 13-151 and 5lipoxygenase products [ 161. LT 
generation has been demonstrated in vitro to occur 
in several cell types including mononuclear phago- 
Abbreviations: HPLC, high-performance liquid chro- 
matography; HTMP, 4-hydroxy-2,2,6,6tetramethyl- 
piperidin-1-oxy1; i.p., intraperitoneally; i.v., intra- 
venously; LT, leukotriene; LPS, iipopolysaccharide or 
endotoxin; RIA, radioimmunoassay 
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cytes of various m~malian species after ap- 
propriate stimulation [2,17-201. 
Inhibitor studies in mice have recently suggested 
a key role for peptide LTs in endotoxin shock 
[21,22]. Taking into consideration that the hepat- 
obiliary secretion has been shown to be the main 
route of elimination for i.v. administered peptide 
LTs [23], we examined the secretion of endogenous 
peptide LTs into bile from endotoxin-treated rats. 
The evidence presented here is to our knowledge 
the first demonstration of peptide LT production 
induced by LPS in vivo. 
2. MATERlA~S AND METHODS 
2.1. Materials 
Highly purified endotoxin from S. minnesota 
R595 was kindly supplied by Dr C Galanos, Max- 
Planck-Institut fiir Immunbiologie, Freiburg, 
FRG. Sodium pentobarbital was from Serva, 
Heidelberg. HTMP from Sigma, St. Louis, MO. 
Tritiated LTC4 and LTD4 (40 Ci/mmol) as well as 
the LTCd-RIA were obtained from New England 
Nuclear, Boston, MA. The unlabeled LTD4 was 
generously provided by Dr V. Fiedler, Bayer AC, 
Wuppertal. 
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2.2. Animals 
Female Wistar rats were obtained from Voss, 
Tuttlingen, FRG. All animals were 12-14 weeks of 
age and were fed and unrestricted diet containing 
20% protein, 38% carbohydrate, 4% fat, of which 
26% were linoleic acid, 0.5% linolenic acid and 
0.2% Ct0-C22 fatty acids (Alma, Kempten, FRG). 
2.3. Bile sampling 
Bile collection was performed with the animals 
under fight pentobarbital anesthesia (0.14 mmol/ 
kg, i.p.) and subsequent bile duct cannulation. Bile 
collection in awake animals was performed as 
follows: a bilio-duodenal anastomosis tube was 
implanted 1 week before the experiment; for bile 
collection a loop of the anastomosis tubing (poly- 
ethylene, outer diameter 0.6 mm) was tapped sub- 
cutaneously. Bile was collected under argon into 
ice-cold methanol containing 1 mmol/l HTMP and 
brought to 80070 methanol with methanol/l mmol/l 
HTMP. After a minimum of 3 h at O”C, these bile 
samples were centrifuged for 10 min at 8OOOxg at 
4°C. Aliquots of the deproteinized supernatants 
were either directly applied to RP-HPLC or sub- 
jected to an extraction for peptide LTs [24] prior 
to RP-HPLC. Before this extraction, methanolic 
bile samples were evaporated at 35°C under 
nitrogen. 
2.4. High-performance liquid chromatography 
RP-HPLC of LTs 125,263 was performed on a 
Cis(ODS)-Hypersil column (4.6 x 250 mm, 5 pm 
particles, Shandon Southern Products, Runcorn, 
England) using a Kontron apparatus with UV 
detection operating at 280 nm. The mobile phases 
were methanol/water/acetic acid (7:3:0.01, by 
vol.), pH 5.4 (solvent I); the same solvent contain- 
ing 1 mmol/l EDTA (solvent II); acetonitrile/ 
water/acetic acid (3:7:0.01, by vol.) pH 5.8 (solvent 
III); the pH values were adjusted with NH40H; the 
flow rates amounted to 1 ml/min. Aliquots of 
deproteinized or extracted bile samples were made 
30% of methanol prior to RP-HPLC. RP-HPLC 
fractions for radioimmunologic analysis were im- 
mediately neutralized with KOH (2 mol/l) and 
stored at -20°C under argon for up to 3 days. 
2.5, L TCd-radioimmunoassay (L TC4-RIA) 
The RIA applied is reported to have the follow- 
ing cross-reactivities: 100% LTC4, 55% LTD4, 9Yo 
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LTE4, 10% LTC4- and LTD4-sulfone, 2% LTE4- 
sulfone, 0.07% S-HETE, 0.006% LTB4, less than 
0.005% other eicosanoids. The detection limit was 
at co.03 pmol LTC4. Aliquots of neutralized RP- 
HPLC fractions were evaporated to dryness at 
room temperature under reduced pressure and re- 
suspended in assay buffer for subsequent radioim- 
munologic analysis; under the conditions employed 
no loss of immunoreactivity was observed. 
3. RESULTS 
3.1. Peptide leukotrienes in bile of endotoxin- 
treated rats 
Intravenous injection of a high dose of endotox- 
in into anesthetized rats resulted in the production 
and hepatobiliary secretion of LTG-like im- 
munoreactive material (fig.1). In bile samples ex- 
tracted for peptide LTs, the major portion of RIA- 
detectable LT resided in a RP-HPLC fraction with 
a retention time of 1.3 f 0.1 relative to LTC4 in 
solvent I (fig-l). Minor amounts of endogenous 
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Fig. 1. LTCd-like immunoreactivity in HPLC- 
fractionated bile extract of endotoxin-treated rats. 1 h 
after endotoxin (from S. ~~~~~sota R595; 15 mglkg, 
iv.), bile was collected from anesthetized animals over 
a 1.5 h period. An aliquot of the deproteinized bile was 
selectively extracted for peptide LTs [24]; upon subse- 
quent RP-HPLC (solvent II), fractions were analyzed by 
LTG-RIA. The dotted line at retention times shorter 
than 10 min indicates underestimation by RIA as high 
LT binding occurred in these fractions. Retention times 
of internal [‘HILT-standards are indicated by arrows. 
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LTD4 were detected in bile of rats during the first 
hour after LPS administration. When LPS was ad- 
ministered to awake animals, the biliary concentra- 
tion of the endogenous peptide LT metabolite in- 
creased significantly within 30 min after LPS and 
returned to the basal level after 2 h (fig.2). Injec- 
tion of 0.9% NaCl did not cause a significant 
change in the biliary concentration of the LTG- 
like immunoreactive material. 
3.2. Comparative HPLC-analyses of biliary 
leukotriene components 
The endogenous LTG-like immunoreactive 
material (figs. 1 and 2) corresponded in its chromat- 
ographic properties to a biliary metabolite of i.v. 
0’ ’ ’ k ’ ’ 
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Fig.2. Production of peptide leukotrienes in endotoxin- 
treated rats. Bile was collected from unanesthetized 
animals by S.C. tapping of a bile fistula implanted 1 week 
prior to the experiment. Biliary LTCd-like immunoreac- 
tivity before and after i.v. injection of NaCl and en- 
dotoxin (LPS, from S. minnesota R595; 15 mg/kg) was 
determined by RIA in fractions after RP-HPLC separa- 
tion (solvent II) of deproteinized samples. The figure 
represents the major immunoreactive material in bile 
eluting with a retention time relative to LTG of 1.3 + 
0.1 (see fig. 1). Horizontal bars indicate concentrations 
in the respective bile sampling period. Mean values + SE 
from 4-5 animals are given. Concentration of LTGlike 
immunoreactivity was significantly elevated above con- 
trol (P<O.O2) 0.25-2 h after LPS as determined by stu- 
dent’s f-test for paired observations. 
b Retention times (mln) 
Fig.3. RP-HPLC analysis of rat bile after i.v. [‘H]LTD4. 
Bile was collected from anesthetized animals during the 
indicated time periods following i.v. administration of 
tracer [‘H]LTD4 (1 &i/kg). Panels represent radioac- 
tivity in HPLC-fractions (solvent II) from 20 ~1 native 
bile after deproteinization; fractions of 1 ml were 
counted for 3H radioactivity. Retention times of internal 
LT standards are indicated by arrows. Note that the 
relative amount of the metabolite eluting between LTG 
and LTD4 increased with time after i.v. [3H]LTD4 
injection. 
injected [3H]LTD4 (fig.3, solvent II), LTD4 (fig.4, 
solvent I) and [3H]LTC4 (solvent II). Using HPLC 
solvent III we confirmed the identical chromato- 
graphic properties of the immunoreactive endo- 
genous LT and the respective metabolite of [3H]- 
LTG, [3H]LTD4, or LTD4 (not shown). This 
metabolite represented a major fraction (about 
30%) of the total biliary radioactivity over a 30 
min period after i.v. injected [3H]LTC4 or 
t3H]LTD4; its relative amount in the respective bile 
samples increased with time (fig.3). 
3.3. Ultraviolet spectra of biliary leukotrienes 
Spectrophotometric analysis of bile components 
after LTD4 (50 nmol/kg, i.v.) demonstrated that 
much of the injected LTD4 appeared in bile 
unmetabolized (absorbance maximum, 280 nm; 
shoulders at 270 and about 290 nm) (fig.4, upper 
right panel). The ultraviolet spectrum of the more 
polar LTD4 metabolite coeluting with the en- 
dogenous immunoreactive LTQ-like material 
(fig. 1) showed an intact peptide LT spectrum with 
the absorbance maximum at 280 nm and shoulders 
at 270 and about 290 nm (fig.4, upper left panel). 
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Fig.4. RP-HPLC profile and ultraviolet spectra of pep- 
tide leukotrienes in bile of rats after i.v. LTD4. Bile was 
collected from anesthetized rats between 0 and 10 min 
after completion of LTD4 administration (50 nmol/kg, 
i.v. within 5 min). Lower panel: RP-HPLC (solvent I) of 
a deproteinized bile aliquot corresponding to 50,~l native 
bile; striped arrows indicate retention times of [3H]LT 
standards. Dotted line represents absorbance of control 
bile. Upper panels: Ultraviolet spectra of corresponding 
Rp-HPLC fractions (open arrows). The two HPLC frac- 
tions were neutralized, evaporated under nitrogen and 
their spectra recorded after resuspension in 50% 
methanol (v/v). 
4. DISCUSSION 
This study provides direct evidence for LPS- 
induced production of peptide LTs in vivo (figs 1 
and 2). As judged from the biliary appearance of 
peptide LTs, LPS triggered a rapid and transient 
generation of peptide LTs that returned to basal 
levels within 2 h after LPS administration (fig.2). 
Under the experimental conditions described, only 
small amounts of LTD4 were eliminated into bile 
of unanesthetized animals. Employing the HPLC- 
system containing acetonitrile as solvent, we ex- 
cluded the appearance of biliary LTC4 to any ap- 
preciable amount. 
The major part of LPS-elicited peptide LTs in 
bile consisted of a metabolite eluting between 
LTG and LTD4 in 3 different HPLC systems. The 
indicated concentration of this peptide LT in bile 
is likely to be an underestimation as it was calcul- 
ated assuming 100% cross-reactivity with the LTC4 
antibody. Taking further into account the im- 
paired hepatobiliary LT elimination after LPS 
treatment [27], one may expect that distinctly 
higher amounts of peptide LTs were produced in 
the animals. 
The structural identity of the main endogenous 
peptide LT found in bile after LPS awaits addi- 
tional characterization. From the comparative 
analyses with injected LTs we conclude that the en- 
dogenous peptide LT is a metabolite of LTC4 and 
LTD4 (figs 3 and 4). Combined analysis of bile ex- 
tracts using HPLC and RIA provides a novel ap- 
proach to the determination of peptide LTs gene- 
rated in vivo under various pathophysiological 
conditions. 
NOTE ADDED IN PROOF 
The endogenous peptide LT described in figs 1 
and 2 has been identified as N-a&yl-LTE4 by 
coelutions on HPLC with standard synthesized 
chemically by G. Weckbecker, Freiburg. 
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